Insider Trading History of O'brien Patrick

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of O'brien Patrick since 2019. This trader's CIK number is 1627183. At the time of last reporting, O'brien Patrick was the COO and General Counsel of Arrowhead Pharmaceuticals, Inc.. (stock ticker symbol ARWR). Also see all insider trading activities at Arrowhead Pharmaceuticals, Inc..


Yearly summary of insider trading at Arrowhead Pharmaceuticals, Inc. (ARWR) by O'brien Patrick

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2025 ARWR 0 $0 37,184 $738,135 0 $0
2024 ARWR 0 $0 33,190 $1,134,076 0 $0
2023 ARWR 0 $0 50,000 $1,929,560 0 $0
2022 ARWR 0 $0 32,500 $2,034,240 60,000 $369,000
2021 ARWR 0 $0 115,000 $9,747,824 90,000 $469,800
2020 ARWR 0 $0 14,625 $882,662 0 $0
2019 ARWR 0 $0 102,000 $1,785,360 0 $0


Insider trading of Arrowhead Pharmaceuticals, Inc. (ARWR) by O'brien Patrick

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2025-01-06 ARWR Sale 29,184 19.89 580,615
2025-01-07 ARWR Sale 8,000 19.69 157,520
2024-01-03 ARWR Sale 8,749 32.60 285,243
2024-01-04 ARWR Sale 1,600 32.63 52,208
2024-01-05 ARWR Sale 22,841 34.88 796,625
2023-01-05 ARWR Sale 15,000 37.39 560,850
2023-01-03 ARWR Sale 17,500 39.11 684,355
2023-01-03 ARWR Sale 17,500 39.11 684,355
2022-12-21 ARWR Option Ex 32,000 6.15 196,800
2022-01-05 ARWR Sale 32,500 62.59 2,034,240
2021-12-31 ARWR Option Ex 28,000 6.15 172,200
2021-02-08 ARWR Option Ex 90,000 5.22 469,800
2021-02-08 ARWR Sale 90,000 88.33 7,950,149
2021-01-06 ARWR Sale 25,000 71.91 1,797,675
2020-01-06 ARWR Sale 14,625 60.35 882,662
2019-05-28 ARWR Sale 30,000 24.88 746,400
2019-01-18 ARWR Sale 72,000 14.43 1,038,960

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by O'brien Patrick (COO and General Counsel of Arrowhead Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.